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OBJECTIVE — Thepurposeofthisstudywastodeterminetheassociationsbetweendiabetes-
related symptom distress, glucose metabolism status, and comorbidities of type 2 diabetes.
RESEARCH DESIGN AND METHODS — This was a cross-sectional sample of 281
individuals with normal glucose metabolism (NGM), 181 individuals with impaired glucose
metabolism (IGM), and 107 subjects with type 2 diabetes. We used the revised type 2 Diabetes
Symptom Checklist (DSC-R) to assess diabetes-related symptom distress.
RESULTS — The total symptom distress score (range 0–100) was relatively low for dia-
betic subjects (mean  SD 8.4  9.4), although it was signiﬁcantly different from that for
subjects with IGM (6.5  7.1) and NGM (6.1  7.9) (F  3.1, 2 d.f., P  0.046). Ischemic
heart disease was associated with elevated DSC-R scores on three subscales, whereas de-
pression showed higher symptom distress levels across all DSC-R domains.
CONCLUSIONS — Worsening glucose metabolism is associated with increasing diabetes-
related symptom distress. This relationship is attenuated by ischemic heart disease and partic-
ularly by depression.
Diabetes Care 31:2268–2270, 2008
T
ype 2 diabetes can seriously affect
patients’ health-related quality of
life (1), and symptom distress has
been recognized as an important patient-
reported outcome (2,3). So far, empirical
dataaboutsymptomdistressinrelationto
glucose metabolism status and comor-
bidities are sparse, especially among sub-
jects with impaired glucose metabolism
(IGM) (pre-diabetes). Therefore, we ana-
lyzed cross-sectional data of the 2000–
2001 follow-up examination from the
Hoorn Study, a population-based cohort
study, to compare levels of diabetes-
related symptom distress among groups
with different glucose metabolism status
(i.e., normal glucose metabolism [NGM],
impaired glucose metabolism [IGM], and
diabetes) and to examine the moderating
effect of complications and comorbidi-
ties, including depression.
RESEARCH DESIGN AND
METHODS— The total study sample
consisted of 569 subjects, 280 men and
289 women, with a mean  SD age of
69.8  6.4 years. Details of the 2000–
2001 follow-up examination from the
Hoorn Study have been described before
(4). All subjects gave written informed
consent. Information about age and sex
wasassessedbymeansofaquestionnaire.
BMI and blood pressure were measured
using standard methods. Hypertension
was deﬁned as a diastolic blood pres-
sure 90 mmHg and/or a systolic blood
pressure 140 mmHg and/or taking
antihypertensive medication. Glucose
metabolism status was based on an oral
glucose tolerance test using the World
Health Organization 1999 diagnostic
criteria (5). Ischemic heart disease was
determined from a 12-lead electro-
cardiogram. Prevalent cardiovascular
disease was assessed by the Rose ques-
tionnaire (6).
Neuropathy was deﬁned as the pres-
ence of impaired foot sensitivity, assessed
with Semmes-Weinstein monoﬁlaments.
Diabetic retinopathy was deﬁned as Wis-
consin grade 1.5 (7), based on retinal
photography. Microalbuminuria was de-
ﬁned as an albumin-to-creatine ratio of
2.0 mg/mmol (8). Depression was as-
sessed using the 20-item Center for Epi-
demiologic Studies Depression Scale
(CES-D) (score 16) (9). Diabetes-
related symptom distress was measured
with the revised version of the revised
type 2 Diabetes Symptom Checklist
(DSC-R) (10).

2 tests (percent) and ANOVA were
performed to study differences in charac-
teristics, comorbidities, and DSC-R vari-
ables for NGM, IGM, and diabetes.
Because previous studies suggest that de-
pression is associated with increased lev-
els of symptom distress (11,12), we
included depression as a covariate in the
ANOVA to sort out the potential interac-
tion between the DSC-R total scores and
NGM,IGM,anddiabetes.Mann-Whitney
U tests were performed for between-
groupcomparisonsregardingDSC-R,i.e.,
1) diabetes versus IGM and 2) diabetes
versus NGM. Student’s t tests were used
to determine the association between co-
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with and without comorbidity. P  0.05
was considered statistical signiﬁcant. All
analyses were performed using SPSS, ver-
sion 11.5 for Microsoft Windows.
RESULTS— ANOVA showed that
worsening glucose metabolism, repre-
sented by NGM (mean  SD 6.1  7.9),
IGM (6.5  7.1), and diabetes (8.4 
9.4), was associated with increasing
DSC-R total scores (F  3.1, 2 d.f., P 
0.046). In addition, we included de-
pression (CES-D score) as a covariate in
the ANOVA to sort out the potential in-
teraction. Virtually the same DSC-R
scores were found for the subjects with
NGM (6.0  7.7), IGM (6.1  7.0), and
diabetes (8.5  9.7), although scores
were not statistically signiﬁcant (F 
0.99, 2 d.f., P  0.245). Mann-Whitney
U tests revealed that diabetic patients
reported a signiﬁcantly greater burden
of neuropathic pain (P  0.033), sensi-
bility symptoms (P  0.004), and total
symptomdistress(P  0.005)thansub-
jects with NGM but not those with IGM
(supplemental Table A1, available in
an online appendix at http://dx.doi.org/
10.2337/dc08-1074).
Subjects with ischemic heart disease
had a signiﬁcantly higher total DSC-R
score compared with subjects with non-
ischemic heart disease. Most strikingly,
both the DSC-R score total and all sub-
scale scores appeared to be 3-fold
higher for subjects with depression
(CES-D score 16) than for those with-
out depression at all three stages of glu-
cose metabolism (Table 1).
CONCLUSIONS— This is the ﬁrst
study to demonstrate the association be-
tween glucose metabolism status and
thelevelofdiabetes-relatedsymptomdis-
tress using the DSC-R score. Worsening
glucose metabolism is associated with in-
creasing diabetes-related symptom dis-
tress. This relationship is attenuated by
ischemic heart disease and by depression
in particular. The results presented pro-
vide supportive evidence of the validity
and reliability of the DSC-R.
Thefactthatsubjectswithdepression
reported signiﬁcantly higher DSC-R lev-
els compared with those without depres-
sion suggests that negative affect has a
strong amplifying effect on diabetes
symptom burden, representing higher ill-
ness intrusiveness. The association be-
tween diabetes symptoms and depressive
moodcouldalsobebidirectional,withdi-
abetes symptoms contributing to the de-
velopment of depressive symptoms (13).
Yet, even after correction for depression
we found that diabetic subjects report
higherlevelsofdiabetessymptomdistress
than subjects with NGM or IGM, under-
scoring the importance of glucose metab-
olism status.
In individuals screened for type 2
diabetes, relatively high levels of symp-
tom distress may indicate comorbid de-
pression and a need for antidepressant
treatment.Likewise,inpatientswithes-
tablisheddiabetes,highsymptomdistress
despite relatively good glycemic control
maypointtoelevatedlevelsofdepression.
New longitudinal research on this com-
plex relationship is warranted to further
understand underlying mechanisms and
todevelopeffectivetherapeuticstrategies.
The strengths of our study are the use
of data from a population-based sample,
the use of a standard measurement to de-
termine glucose metabolism status (i.e.,
an oral glucose tolerance test), the avail-
ability of information on comorbidities,
and the use of the validated DSC-R to de-
termine diabetes-related symptom dis-
tress. There are also limitations. This
present study has a cross-sectional de-
sign. Further prospective research should
help to clarify the course of symptom dis-
tress over time across different stages of
glucose metabolism. In addition, deter-
mining the impact of different treatment
strategies (i.e., diet, blood glucose–
lowering drugs, and insulin) on the
DSC-Rlevelsamongdiabetespatientswas
beyond the scope of this study. However,
given the increasing importance of pa-
tient-reported outcomes, future research-
ers should carefully explore the impact of
diabetes medication on symptom distress
as a measure of health-related quality of
life.
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